Licensing Opportunity – Next-Generation CAR-T for Multiple Myeloma
July 8, 2025
Utrecht Holdings is proud to offer a patent-pending CAR-T cell therapy platform developed by researchers at UMC Utrecht.
Utrecht Holdings is proud to offer a patent-pending CAR-T cell therapy platform developed by researchers at UMC Utrecht.
Utrecht Holdings is the Utrecht University and UMC Utrecht in-house partner for knowledge transfer and start-ups.
Menu
Visiting address
Contact Us
T: 085 – 087 63 69
BTW-nummers (VAT numbers): UU Holding BV: NL806771604B01 || UMCU Holding BV: NL806125214B01